-
Detailed Description
CAS Number: 24729-96-2
Molecular Formula: C18H34ClN2O8PS
Molecular Weight: 504.96
Mechanism of Action: Lincosamides inhibit bacterial protein synthesis by binding the 50S ribosomal subunit and interfering with tRNA activity during translation.
Storage Conditions: Store at room temperature in an airtight container
Tariff Code: 2941.90.5000
-
Applications
Spectrum: Clindamycin is a broad-spectrum antibiotic targeting primarily Gram-positive and Gram-negative bacteria such as Clostridium and Bacteroides species. It is also effective against protozoa.
Microbiology Applications: Clindamycin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative anaerobes. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative concentration ranges include:
- Bacteroides fragilis 0.25 µg/mL - 4 µg/ml
- Clostridium difficile 0.25 µg/mL - 32 µg/mL
For representative MIC data, click here.Eukaryotic Cell Culture Applications: HIV-infected cells (MOLT3 cells) were incubated with increasing concentrations of Clindamycin with no impact on cell death (Wijsman et al, 2013).
The effects of Clindamycin and its metabolites on mammalian cell lines (mouse leukemia L1210, human oral carcinoma KB, human acute myelogenous leukemia RPMI 6410, and human lymphocyte RPMI 1788) were evaluated. Metabolites clindamycin sulfoxide and clindamycose were nontoxic, whereas N-demethyl clindamycin showed cytotoxic effects in culture (Li et al, 1977). -
Specifications
Form: powder
Appearance: White or almost white crystalline powder
Source: Semi-synthetic
Water Content (Karl Fischer): ≤6.0%
pH: 3.5-4.5
Assay: ≥758 µg/mg
-
Technical Data
Solubility: freely soluble in aqueous solution.
-
References
References:
Dhawan VK and Thadepalli H (1982) Clindamycin: A review of fifteen years of experience. Clin. Infect. Dis. 4(6):1133-1153 PMID 6818656
Li LH, Kuentzel K L, Shugars KD and Bhuyan BK (1977) Cytotoxicity of several marketed antibiotics on mammalian cells in culture. J. Antibiot (Tokyo) 30(6):506-512 PMID 560364
Lovmar M and Tanel T (2003) The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Molec. Microbiol. 330(5 ): 1005-014 PMID 12860123
Magerlein BJ et al (1966) Chemical modification of lincomycin. Antimicrob Agents Chemother. 6:727 PMID 5985307
Wijsman JA, Dekaban GA and Rieder MJ (2013) Differential toxicity of reactive metabolites of Clindamycin and sulfonamides in HIV-infected cells: Influence of HIV infection on clindamycin toxicity in vitro. J. Clin. Pharmacol. 45(3):346-351 PMID 15703369
Clindamycin Phosphate (Clindamycin-2-phosphate) is a broad-spectrum antibiotic and antiparasitic agent. It is a semi-synthetic derivative of Lincomycin, a natural lincosamide from Streptomyces lincolnensis. Clindamycin Phosphate is freely soluble in water.
We also offer:
CAS Number: 24729-96-2
Molecular Formula: C18H34ClN2O8PS
Molecular Weight: 504.96
Mechanism of Action: Lincosamides inhibit bacterial protein synthesis by binding the 50S ribosomal subunit and interfering with tRNA activity during translation.
Storage Conditions: Store at room temperature in an airtight container
Tariff Code: 2941.90.5000
Spectrum: Clindamycin is a broad-spectrum antibiotic targeting primarily Gram-positive and Gram-negative bacteria such as Clostridium and Bacteroides species. It is also effective against protozoa.
Microbiology Applications: Clindamycin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative anaerobes. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative concentration ranges include:
- Bacteroides fragilis 0.25 µg/mL - 4 µg/ml
- Clostridium difficile 0.25 µg/mL - 32 µg/mL
Eukaryotic Cell Culture Applications: HIV-infected cells (MOLT3 cells) were incubated with increasing concentrations of Clindamycin with no impact on cell death (Wijsman et al, 2013).
The effects of Clindamycin and its metabolites on mammalian cell lines (mouse leukemia L1210, human oral carcinoma KB, human acute myelogenous leukemia RPMI 6410, and human lymphocyte RPMI 1788) were evaluated. Metabolites clindamycin sulfoxide and clindamycose were nontoxic, whereas N-demethyl clindamycin showed cytotoxic effects in culture (Li et al, 1977).
Form: powder
Appearance: White or almost white crystalline powder
Source: Semi-synthetic
Water Content (Karl Fischer): ≤6.0%
pH: 3.5-4.5
Assay: ≥758 µg/mg
Solubility: freely soluble in aqueous solution.
References:
Dhawan VK and Thadepalli H (1982) Clindamycin: A review of fifteen years of experience. Clin. Infect. Dis. 4(6):1133-1153 PMID 6818656
Li LH, Kuentzel K L, Shugars KD and Bhuyan BK (1977) Cytotoxicity of several marketed antibiotics on mammalian cells in culture. J. Antibiot (Tokyo) 30(6):506-512 PMID 560364
Lovmar M and Tanel T (2003) The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Molec. Microbiol. 330(5 ): 1005-014 PMID 12860123
Magerlein BJ et al (1966) Chemical modification of lincomycin. Antimicrob Agents Chemother. 6:727 PMID 5985307
Wijsman JA, Dekaban GA and Rieder MJ (2013) Differential toxicity of reactive metabolites of Clindamycin and sulfonamides in HIV-infected cells: Influence of HIV infection on clindamycin toxicity in vitro. J. Clin. Pharmacol. 45(3):346-351 PMID 15703369